Hollywood, California Clinical Trials

A listing of Hollywood, California clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 77 clinical trials
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

factor ix
fitusiran
antihemophilic factor
bethesda assay
hemophilia
Investigational Site Number 8400002
 (6.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +10 other locations
Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants  

Primary Objective: To assess the safety profile of each SP0202 formulation and Prevnar 13 in toddlers and infants (after each and any injection). To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after the administration of one dose in toddlers (Groups …

Investigational Site Number 8400059
 (3.5 away)
  • 0 views
  • 19 Feb, 2024
  • +31 other locations
An Open-label Ascending Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)

Primary Objective: To describe the pharmacokinetic (PK) profile of sarilumab in patients aged 2-17 years with Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) in order to identify the dose and regimen for adequate treatment of this population Secondary Objective: To describe the pharmacodynamic (PD) profile, the efficacy and the long-term safety of …

arthritis
sarilumab
rheumatoid factor
anti-rheumatic drugs
disease modifying antirheumatic drugs
Investigational Site Number 8400416
 (2.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +33 other locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

factor ix
fitusiran
antihemophilic factor
bethesda assay
hemophilia
Investigational Site Number 8400002
 (2.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +10 other locations
Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

Primary Objectives: To assess the efficacy of lademirsen (SAR339375) in reducing the decline in renal function To assess the safety and tolerability of lademirsen (SAR339375) in subjects with Alport syndrome Secondary Objectives: To assess plasma pharmacokinetic (PK) parameters of the parent compound and its metabolites To assess the potential formation …

Investigational Site Number :8400002
 (6.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +22 other locations
None

Los Angeles Cancer Network
 (4.4 away) Contact site
  • 0 views
  • 19 May, 2025
  • +19 other locations
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer ALCHEMIST Chemo-IO Study

This phase III ALCHEMIST trial compares the addition of pembrolizumab to usual chemotherapy versus usual chemotherapy for the treatment of stage IB, II, or IIIA non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the …

absolute neutrophil count
squamous non-small cell lung cancer
stage iia lung squamous cell carcinoma ajcc v7
squamous non-small cell lung carcinoma
EGFR
Providence Saint Joseph Medical Center/Disney Family Cancer Center
 (4.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +358 other locations
A Study to Evaluate NT219 Alone and in Combination With ERBITUX (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer

This is a phase 1/2, multi-center study with an open-label, dose escalation phase followed by a single-arm expansion phase to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 alone and in combination with ERBITUX (cetuximab) in adults with recurrent and/or metastatic solid tumors.

pd-l1
serum pregnancy test
squamous cell carcinoma of head and neck
solid tumors
brain metastasis
The Angeles Clinic and Research Institute
 (7.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +5 other locations
Dupilumab Asthma Sleep Study

Primary Objective: To assess the effect of dupilumab on sleep Secondary Objectives: To evaluate the effect of dupilumab on additional patient reported sleep outcomes To evaluate the effect of dupilumab on objective sleep assessment To evaluate the effect of dupilumab on asthma symptoms To evaluate the effect of dupilumab on …

polysomnography
forced expiratory volume
leukotriene receptor antagonist
eosinophil count
fractional exhaled nitric oxide
Investigational Site Number 8400009
 (2.8 away) Contact site
  • 0 views
  • 24 Nov, 2025
  • +10 other locations
None

Los Angeles Cancer Network
 (4.4 away) Contact site
  • 0 views
  • 19 May, 2025
  • +12 other locations